News Search Results
Oct 08, 2025, 08:30 ET Ensure Product Efficacy and Patient Safety with Benzalkonium Chloride, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Oct 08, 2025, 08:30 ET ImmunoVec Launches from Stealth with up to $40.7 Million ARPA-H EMBODY Award to Advance In Vivo Cell Engineering Platform for Autoimmune Diseases
LOS ANGELES, Oct. 8, 2025 /PRNewswire/ -- ImmunoVec, a biotechnology company pioneering a novel approach to in vivo cell engineering, today announced its launch from stealth with an up to $40.7 million award from
More news about: ImmunoVec
Oct 08, 2025, 08:05 ET Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
Calif., Oct. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced the first patient has been enrolled in the dose expansion phase of the ongoing
More news about: Rigel Pharmaceuticals, Inc.
Oct 08, 2025, 08:02 ET Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform
compliance. Hoth's AI initiative complements its broader strategy of digital transformation and innovation in biotechnology, enabling partnerships with advanced AI-driven platforms and life-science data companies to optimize development timelines, reduce costs, and improve
More news about: Hoth Therapeutics, Inc.
Oct 08, 2025, 08:01 ET TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
(NASDAQ: RNAZ) ("TransCode or the "Company") announced today that it entered into a definitive agreement to acquire Polynoma LLC, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candidate, seviprotimut-L, a novel polyvalent shed antigen vaccine for the adjuvant
More news about: TransCode Therapeutics, Inc.
Oct 08, 2025, 08:00 ET CREATE Medicines Strengthens Executive Team with Appointment of Veteran Biopharma Leader Allan L. Shaw as CFO and CBO
CAMBRIDGE, Mass., Oct. 8, 2025 /PRNewswire/ -- CREATE Medicines, a clinical-stage biotechnology company pioneering RNA-based in vivo multi-immune programming, today announced the appointment of Allan L. Shaw as Chief Financial Officer (CFO)
More news about: CREATE Medicines, Inc.
Oct 08, 2025, 08:00 ET Arthrosi Secures $153 Million in Series E Financing to Complete Pivotal Development of Pozdeutinurad for the Treatment of Gout and Tophaceous Gout
SAN DIEGO, Oct. 8, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Arthrosi Therapeutics
Oct 08, 2025, 08:00 ET BIOVAXYS APPOINTS FORMER SANOFI VACCINES EXECUTIVE TO BOARD OF DIRECTORS
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Oct 08, 2025, 07:30 ET Hunting Parasites to Save Animal Lives - From the Deep Sea to the Family Dog: MiDOG Expands Veterinary Genomics with First Set of Parasite Reference Genomes in Collaboration with the University of Nebraska's Harold W. Manter Laboratory of Parasitology
has released its first set of parasite reference genomes for companion animals and wildlife, publicly available through the National Center for Biotechnology Information (NCBI). This milestone extends MiDOG's DNA-based diagnostics beyond bacteria, viruses, and fungi, addressing a critical gap in animal
More news about: MiDOG Animal Diagnostics
Oct 08, 2025, 03:00 ET Complement Therapeutics Receives FDA IND Clearance to Advance CTx001 into Opti-GAIN, a Phase I/II Clinical Trial in Geographic Atrophy secondary to AMD
MUNICH, Oct. 8, 2025 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), a biotechnology company developing next-generation therapeutics for complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA)
More news about: Complement Therapeutics
Oct 08, 2025, 01:28 ET Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer
Spain. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide
More news about: Oncoinvent AS
Oct 08, 2025, 01:24 ET Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer
Spain. About Oncoinvent Oncoinvent is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. The lead product candidate, Radspherin®, uses the alpha-emitting radionuclide
More news about: Oncoinvent AS
Oct 07, 2025, 18:00 ET Cyteph Completes Recruitment for Phase I Clinical Trial of CYT-101 in Patients with Recurrent Glioblastoma Multiforme Brain Cancer
Oct. 7, 2025 /PRNewswire/ -- Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully completed recruitment for its
More news about: Cyteph Pty Ltd
Oct 07, 2025, 17:31 ET AHR Agonists Market Trends Signal Promising Growth in Immunology and Dermatology Therapeutics | DelveInsight
Advancements in Drug Discovery and Precision Medicine Recent advancements in biotechnology and genomics have enhanced the understanding of AhR's role in various diseases, leading to the development of novel therapeutic strategies. The
More news about: DelveInsight Business Research, LLP
Oct 07, 2025, 17:30 ET BIOVAXYS ANNOUNCES LIFE OFFERING
receive the required regulatory approvals. With regards to BioVaxys' business, there are a number of risks that could affect the development of its biotechnology products, including, without limitation, the need for additional capital to fund clinical trials, its lack of operating history, uncertainty about
More news about: BioVaxys Technology Corp.
Oct 07, 2025, 17:15 ET Recycled Plastic Market Size to Reach US$ 132.55 Billion by 2035 with 8.25% CAGR | Analysis by Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Oct 07, 2025, 17:00 ET Nanalysis announces support from Wiley for NMR Instruments in KnowItAll 2026
layers that can simplify spectral interpretation and help include it in routine laboratory analysis workflows for customers in pharmaceuticals, biotechnology, materials, polymers etc. To this end, we are pleased to partner with Wiley's KnowItAll to ensure that our users have access to their state-of-the-art
More news about: Nanalysis Scientific Corp.
Oct 07, 2025, 12:15 ET Rubin Rudman Adds Kelly Aylward as a Partner in Trusts & Estates Group
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; regulated industries, public entities and municipalities; insurance companies and their insureds; educational
More news about: Rubin Rudman
Oct 07, 2025, 10:10 ET IoT in Healthcare Market to Surpass USD 594.5 Billion by 2035 -- AI & Smart Devices Power the Next Wave of Digital Health: Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Oct 07, 2025, 10:01 ET Multi-Plex Immunoassays Market to Reach US$ 6.90 Billion by 2033 as Precision Medicine and Biomarker Discovery Fuel Global Adoption | DataM Intelligence
By End-User Pharmaceutical & biotechnology companies led with -US$ 1.4 billion in 2024, supported by demand in biomarker validation and immuno-oncology pipelines.Hospitals
More news about: DataM Intelligence 4 Market Research LLP
Oct 07, 2025, 09:03 ET QuantiPath Appoints Jeff Nauseda as Director of Market Development -- Bolstering Beef & Pet Food Reach Ahead of GenoPATHX Launch
DENVER, Oct. 7, 2025 /PRNewswire/ -- QuantiPath (quantipath.bio), the biotechnology company advancing genomic pathogen diagnostics for food safety, today announced the appointment of Jeff Nauseda as Director of Market Development, with
More news about: QuantiPath
Oct 07, 2025, 09:00 ET Precision NeuroMed Granted FDA Orphan Drug Designation by U.S. FDA for Treatment of Glioblastoma Multiforme (GBM)
PNM), a clinical-stage biotechnology company pioneering advanced drug delivery technologies for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration
More news about: Precision NeuroMed
Oct 07, 2025, 09:00 ET Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion
(NASDAQ: GTBP), Leap Therapeutics, Inc. (NASDAQ: LPTX), IO Biotech (NASDAQ: IOBT), Celcuity Inc. (NASDAQ: CELC), and MAIA Biotechnology, Inc. (NYSE-American: MAIA).
More news about: USA News Group
Oct 07, 2025, 09:00 ET Introducing Benchling AI
in their workflows, connected to structured data. The result: faster teams and better molecules. Benchling's mission is to unlock the power of biotechnology and make breakthroughs possible for all.
More news about: Benchling
Oct 07, 2025, 08:34 ET GeneVentiv Therapeutics Selected into NHLBI Catalyze Program to Fund IND-Enabling Toxicology Study for GENV-HEM
RALEIGH, N.C., Oct. 7, 2025 /PRNewswire/ -- GeneVentiv Therapeutics, a biotechnology company pioneering next-generation gene therapies for rare diseases, today announced that it has been selected into the Catalyze Program of the
More news about: GeneVentiv Therapeutics